Compare Stocks → Move Your Money Before May 22 (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CLSNNASDAQ:GANXOTCMKTS:HBPCFNASDAQ:NERVNASDAQ:ONCS Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLSNImunon$2.22$1.80▼$15.75$13.91M2.27150,471 shs711 shsGANXGain Therapeutics$2.95-3.9%$4.01$2.00▼$5.65$47.85M0.43153,693 shs136,752 shsHBPCFHelix BioPharma$0.14$0.14$0.14▼$0.15$31.59M-0.1N/AN/ANERVMinerva Neurosciences$2.46+1.2%$3.34$2.29▼$13.49$17.20M0.2199,911 shs2,977 shsONCSOncoSec Medical$0.52$0.18▼$20.46$1.26M1.992.22 million shs52.49 million shsBeginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLSNImunon0.00%0.00%0.00%0.00%0.00%GANXGain Therapeutics-3.76%-2.54%-19.21%-18.13%-40.27%HBPCFHelix BioPharma0.00%0.00%0.00%-5.03%-5.81%NERVMinerva Neurosciences-2.78%-2.39%-4.67%-69.90%-5.77%ONCSOncoSec Medical0.00%0.00%0.00%0.00%-68.50%Move Your Money Before May 1 (Ad)Did you know that the IRS has allegedly been using AI to spy on the bank accounts of American citizens? Click here to get the full story before May 1. MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLSNImunonN/AN/AN/AN/AN/AN/AN/AN/AGANXGain Therapeutics3.1003 of 5 stars3.53.00.00.03.82.50.6HBPCFHelix BioPharmaN/AN/AN/AN/AN/AN/AN/AN/ANERVMinerva Neurosciences3.6227 of 5 stars3.05.00.04.61.80.00.0ONCSOncoSec MedicalN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLSNImunonN/AN/AN/AN/AGANXGain Therapeutics3.00Buy$8.50188.14% UpsideHBPCFHelix BioPharmaN/AN/AN/AN/ANERVMinerva Neurosciences2.00Hold$11.00347.15% UpsideONCSOncoSec MedicalN/AN/AN/AN/ACurrent Analyst RatingsLatest ONCS, GANX, HBPCF, CLSN, and NERV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/25/2024GANXGain TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.004/23/2024GANXGain TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$9.004/1/2024GANXGain TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.003/27/2024GANXGain TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.002/27/2024NERVMinerva NeurosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$11.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLSNImunon$500K0.00N/AN/A$9.66 per share0.00GANXGain Therapeutics$50K956.98N/AN/A$0.97 per share3.04HBPCFHelix BioPharmaN/AN/AN/AN/AN/AN/ANERVMinerva NeurosciencesN/AN/AN/AN/A($4.07) per shareN/AONCSOncoSec MedicalN/AN/AN/AN/A$3.42 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLSNImunon-$20.77MN/A0.00N/AN/A-5,229.80%-50.18%-36.94%N/AGANXGain Therapeutics-$22.27M-$1.71N/AN/AN/AN/A-193.03%-123.21%5/10/2024 (Estimated)HBPCFHelix BioPharma-$4.69M-$0.04N/A∞N/AN/A-817.64%-308.71%6/12/2024 (Estimated)NERVMinerva Neurosciences-$30M-$4.65N/AN/AN/AN/AN/A-50.27%5/20/2024 (Estimated)ONCSOncoSec Medical-$34.18M-$15.29N/AN/AN/AN/A-868.29%-160.61%N/ALatest ONCS, GANX, HBPCF, CLSN, and NERV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/26/2024Q4 2023GANXGain Therapeutics-$0.32-$0.29+$0.03-$0.29N/AN/A2/22/2024Q4 2023NERVMinerva Neurosciences-$0.88-$1.19-$0.31-$1.19N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLSNImunonN/AN/AN/AN/AN/AGANXGain TherapeuticsN/AN/AN/AN/AN/AHBPCFHelix BioPharmaN/AN/AN/AN/AN/ANERVMinerva NeurosciencesN/AN/AN/AN/AN/AONCSOncoSec MedicalN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLSNImunon0.136.526.52GANXGain Therapeutics0.043.593.59HBPCFHelix BioPharmaN/A1.461.46NERVMinerva NeurosciencesN/A12.5712.58ONCSOncoSec MedicalN/A0.890.89OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLSNImunon12.97%GANXGain Therapeutics11.97%HBPCFHelix BioPharmaN/ANERVMinerva Neurosciences34.56%ONCSOncoSec Medical8.69%Insider OwnershipCompanyInsider OwnershipCLSNImunon4.66%GANXGain Therapeutics11.00%HBPCFHelix BioPharma7.60%NERVMinerva Neurosciences6.40%ONCSOncoSec Medical1.32%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCLSNImunon277.10 million6.77 millionOptionableGANXGain Therapeutics2816.22 million14.44 millionOptionableHBPCFHelix BioPharma9229.44 million212.00 millionNot OptionableNERVMinerva Neurosciences96.99 million6.55 millionNot OptionableONCSOncoSec Medical404.55 million4.49 millionNot OptionableONCS, GANX, HBPCF, CLSN, and NERV HeadlinesSourceHeadlineIs OncoSec Medical Inc (ONCSQ) Stock a Good Investment?aaii.com - June 29 at 2:37 AMONCS - OncoSec Medical Incorporatedfinance.yahoo.com - June 24 at 8:41 AM0 analysts rank ONCS stock as an Overweightknoxdaily.com - June 23 at 6:54 PMWhy Is OncoSec Medical (ONCS) Stock Up 100% Today?markets.businessinsider.com - June 23 at 8:53 AMWhy John Wiley & Sons Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Sessionmsn.com - June 15 at 2:49 PMWhy Is OncoSec Medical (ONCS) Stock Down 48% Today?msn.com - June 15 at 9:48 AMOncoSec Announces Closing of $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rulesfinance.yahoo.com - May 18 at 8:59 PMOncoSec Medical plunges 35% lower on sale of 1.4M shares of common stockmsn.com - May 16 at 4:15 PMOncoSec Announces $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rulesfinance.yahoo.com - May 16 at 4:15 PMOncoSec is encouraged after FDA meeting to discuss proposed neoadjuvant melanoma clinical programfinance.yahoo.com - May 16 at 9:56 AMOncoSec Receives $3.49 Million to Strengthen its Balance Sheet After Selling its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Authority NOL Programfinance.yahoo.com - April 27 at 8:26 AMOncoSec Announces Closing of $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rulesfinance.yahoo.com - April 11 at 5:48 PMWhy OncoSec Medical Shares Are Soaring Todaymsn.com - April 10 at 4:15 PMOncoSec Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rulesfinance.yahoo.com - April 10 at 4:15 PMOncoSec Medical Inc (ONCS) is lower by 6.15% Tuesday In Premarket Tradingbenzinga.com - April 6 at 7:57 PMOncoSec Shares Disappointing Results From Skin Cancer Combo Therapy Trial, Sets Stage For Neoadjuvant Setting Studyfinance.yahoo.com - April 3 at 3:57 PMOncoSec crashes ~60% after TAVO-EP, Keytruda combo fails phase 2 skin cancer trialmsn.com - April 3 at 10:57 AMOncoSec Announces Clinical Data of the KEYNOTE-695 Trial Assessing TAVO™-EP in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Melanoma Refractory to anti-PD-1 Treatmentfinance.yahoo.com - April 3 at 10:57 AMOncoSec Medical Withdraws Planned Offering, Shares Rise Over 50%marketwatch.com - March 1 at 8:56 AMWhy is OncoSec Medical (ONCS) Stock Up 91% Today?msn.com - March 1 at 8:56 AMONCS.OQ - | Stock Price & Latest News | Reutersreuters.com - January 16 at 7:08 PMOncoSec Medical Stock (NASDAQ:ONCS), Quotes and News Summarybenzinga.com - January 5 at 3:51 PMPeering Into OncoSec Medical's Recent Short Interestmsn.com - December 8 at 5:34 PMOncoSec to Present at the RHK Capital Disruptive Growth Conference on December 6, 2022finance.yahoo.com - December 5 at 1:28 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsImunonNASDAQ:CLSNCelsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.Gain TherapeuticsNASDAQ:GANXGain Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of allosteric therapies. Its lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase 1 clinical trial. Its drug discovery platform Magellan identifies novel allosteric binding sites on disease-implicated proteins and exploits untapped opportunities, by pinpointing pockets that cannot be found or drugged with current technologies. The company's platform is enhanced with new AI and machine-learning tools and virtual screening capabilities to access the emerging on-demand compound libraries covering chemical spaces of approximately 50 billion compounds. It deploys its platform by accelerating drug discovery and unlocking novel disease-modifying treatments for untreatable or difficult-to-treat disorders, including neurodegenerative diseases, rare genetic disorders, and oncology. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.Helix BioPharmaOTCMKTS:HBPCFHelix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. The company is headquartered in Toronto, Canada.Minerva NeurosciencesNASDAQ:NERVMinerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.OncoSec MedicalNASDAQ:ONCSOncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's product pipeline includes KEYNOTE-695, which is in Phase 2 trial for the treatment of advanced melanoma; TAVO + SARS-CoV-2 spike glycoprotein, which is in Phase 1 clinical trial for the treatment of COVID-19; and TAVO + epacadostat + pembrolizumab, which is in Phase 1 clinical trial for the treatment of squamous cell carcinoma head and neck cancer. Its pipeline also comprises TAVO +nivolumab, which is in Phase 2 clinical trial for the treatment of breast cancer; TAVO + CXCL9 for the treatment of solid tumors; and OMS-100 and OMS-102, which are in Phase 2 clinical trial for the treatment of metastatic melanoma. OncoSec Medical Incorporated has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890; and a research collaboration with Duke University's Center for Applied Therapeutics to evaluate TAVO in combination or sequenced with a HER2-plasmid vaccine. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was incorporated in 2008 and is headquartered in Pennington, New Jersey. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.